Live Breaking News & Updates on Ourse Ikt Us45719w1062

Stay updated with breaking news from Ourse ikt us45719w1062. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

BOSTON and ATLANTA, May 8, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of. | May 8, 2023 ....

United States , Miltonh Werner , Alex Lobo , Inhibikase Or Company , Inhibikase Therapeutics Inc , Prnewswire Inhibikase Therapeutics Inc , Company Contact , Sternir Inc , Abelson Tyrosine Kinases , Abelson Tyrosine Kinase , Ableson Tyrosine , Multiple System Atrophy , Inhibikase Therapeutics , Nc Stock Exchange , Press Release , Ourse Ikt Us45719w1062 ,

Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, March 31, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of. | March 31, 2023 ....

United States , Miltonh Werner , Alex Lobo , Sternir Inc , Inhibikase Or Company , Inhibikase Therapeutics Inc , Exchange Commission , Prnewswire Inhibikase Therapeutics Inc , Office Of Inhibikase , Drug Administration , Company Contact , Abelson Tyrosine Kinases , Multiple System Atrophy , Chief Executive Office , Stable Phase Chronic Myelogenous , Upcoming Milestones , Investigational New Drug , Science Translational Medicine , Chronic Myelogenous Leukemia , Abelson Tyrosine Kinase , Ableson Tyrosine , Private Securities Litigation Reform Act , Inhibikase Therapeutics , Nc Stock Exchange , Press Release , Ourse Ikt Us45719w1062 ,